Parkinson’s disease is a condition which causes damage to certain parts of the brain. Most people with Parkinson’s start to develop symptoms when they are over the age of 50, but around one in 20 people with the condition first experience symptoms under the age of 40, according to the NHS. The symptoms of Parkinson’s usually develop gradually and are mild at first, so it may not always be obvious you have the condition. There are many different symptoms associated with the disease, but the three main ones involve physical movement.
ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs